Download Files:
PF-06260933
$144 – $1,020
Products Details
Product Description
– PF-06260933 is an orally active and highly selective inhibitor of MAP4K4 with IC50s of 3.7 and 160 nM for kinase and cell, respectively.
Web ID
– HY-19562
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C16H13ClN4
References
– [1]Ammirati M, et al. Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment. ACS Med Chem Lett. 2015 Oct 6;6(11):1128-33.|[2]Roth Flach RJ, et al. Endothelial protein kinase MAP4K4 promotes vascular inflammation and atherosclerosis. Nat Commun. 2015 Dec 21;6:8995.
CAS Number
– 1811510-56-1
Molecular Weight
– 296.75
Compound Purity
– 99.67
SMILES
– NC1=C(C2=CC=C(Cl)C=C2)C=C(C(C=N3)=CC=C3N)C=N1
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology
Solubility
– DMSO : 30 mg/mL (ultrasonic;warming)
Target
– MAP4K
Isoform
– MAP4K4/HGK
Pathway
– MAPK/ERK Pathway
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
